• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Lodoxamide tromethamine Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755110

Lodoxamide tromethamine is a medication of mast cell-mediated allergic disease. It is used for the treatment,of prophylaxis. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Lodoxamide tromethamine, Inhibitor
Full Product Name
Lodoxamide tromethamine
Product Synonym Names
U-42585E
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
553.9
Solubility
DMSO: 20mg/mL (36.11mM) Need ultrasonic and warming
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C19H28ClN5O12
SMILES
N#CC1=CC(NC(C(O)=O)=O)=C(Cl)C(NC(C(O)=O)=O)=C1.OCC(CO)(N)CO.OCC(CO)(N)CO
CAS Number
63610-09-3
Target & IC50
Others
In Vitro
Lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized when given intravenously, orally, or intrabronchially by aerosol. Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. anesthetized rhesus monkeys[1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance[2]. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep[3].

Structure of Lodoxamide tromethamine, inhibitor

Lodoxamide tromethamine Inhibitor – Cat# MBS5755110

Product References and Citations for Lodoxamide tromethamine, inhibitor

Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94.
Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94.
Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7.
Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7.
Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment,of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90.
Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment,of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90.

Other Notes

Small volumes of Lodoxamide tromethamine, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Lodoxamide tromethamine purchase

MBS5755110 is an inhibitor targeting Lodoxamide tromethamine.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000